Cargando…
A potent tumor-selective ERK pathway inactivator with high therapeutic index
FDA-approved BRAF and MEK small molecule inhibitors have demonstrated some level of efficacy in patients with metastatic melanomas. However, these “targeted” therapeutics have a very low therapeutic index, since these agents affect normal cells, causing undesirable, even fatal, side effects. To addr...
Autores principales: | Zuo, Zehua, Liu, Jie, Sun, Zhihao, Silverstein, Rachel, Zou, Meijuan, Finkel, Toren, Bugge, Thomas H, Leppla, Stephen H, Liu, Shihui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308561/ https://www.ncbi.nlm.nih.gov/pubmed/35899070 http://dx.doi.org/10.1093/pnasnexus/pgac104 |
Ejemplares similares
-
ERK and c-Myc signaling in host-derived tumor endothelial cells is essential for solid tumor growth
por: Zuo, Zehua, et al.
Publicado: (2022) -
Identification of the transcription factor Miz1 as an essential regulator of diphthamide biosynthesis using a CRISPR-mediated genome-wide screen
por: Liu, Jie, et al.
Publicado: (2020) -
Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation
por: Liu, Shihui, et al.
Publicado: (2017) -
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
por: Jacob, Sheeba, et al.
Publicado: (2022) -
Characterization of a Chinese Hamster Ovary Cell Mutant Having a Mutation in Elongation Factor-2
por: Gupta, Pradeep K., et al.
Publicado: (2010)